↓ Skip to main content

Intravenous immunoglobulin for Guillain-Barré syndrome

Overview of attention for article published in Cochrane database of systematic reviews, September 2014
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news
41 news outlets
blogs
3 blogs
twitter
4 tweeters
facebook
1 Facebook page
wikipedia
1 Wikipedia page
googleplus
1 Google+ user

Citations

dimensions_citation
132 Dimensions

Readers on

mendeley
291 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intravenous immunoglobulin for Guillain-Barré syndrome
Published in
Cochrane database of systematic reviews, September 2014
DOI 10.1002/14651858.cd002063.pub6
Pubmed ID
Authors

Richard AC Hughes, Anthony V Swan, Pieter A van Doorn

Abstract

Guillain-Barré syndrome (GBS) is an acute, paralysing, inflammatory peripheral nerve disease. Intravenous immunoglobulin (IVIg) is beneficial in other autoimmune diseases. This is an update of a review first published in 2001 and previously updated in 2003, 2005, 2007, 2010 and 2012. Other Cochrane systematic reviews have shown that plasma exchange (PE) significantly hastens recovery in GBS compared with supportive treatment alone, and that corticosteroids alone are ineffective.

Twitter Demographics

The data shown below were collected from the profiles of 4 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 291 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 5 2%
Fiji 1 <1%
Canada 1 <1%
Norway 1 <1%
Peru 1 <1%
Belgium 1 <1%
Spain 1 <1%
Netherlands 1 <1%
Unknown 279 96%

Demographic breakdown

Readers by professional status Count As %
Student > Master 50 17%
Student > Bachelor 42 14%
Researcher 34 12%
Student > Postgraduate 32 11%
Other 27 9%
Other 79 27%
Unknown 27 9%
Readers by discipline Count As %
Medicine and Dentistry 143 49%
Nursing and Health Professions 23 8%
Neuroscience 22 8%
Agricultural and Biological Sciences 14 5%
Pharmacology, Toxicology and Pharmaceutical Science 14 5%
Other 36 12%
Unknown 39 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 358. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2018.
All research outputs
#27,219
of 12,527,219 outputs
Outputs from Cochrane database of systematic reviews
#54
of 8,923 outputs
Outputs of similar age
#464
of 211,476 outputs
Outputs of similar age from Cochrane database of systematic reviews
#3
of 210 outputs
Altmetric has tracked 12,527,219 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,923 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 211,476 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 210 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 98% of its contemporaries.